Diagnostics

A preview of the INVEST Precision Medicine conference June 9-11

  • by

The conference highlights the intersections of technology and life sciences through the prism of precision medicine. The topics at the conference span pediatric innovation in precision medicine, how tech companies are addressing clinical trial challenges, supply chain management, and more.

FDA greenlights two more over-the-counter Covid-19 tests

  • by

The Food and Drug Administration gave an emergency use authorization to two more over-the-counter Covid-19 tests that can be used without a prescription. They include Abbott’s BinaxNow test and an at-home test developed by Quidel Corp. 

 FDA OKs another over-the-counter Covid-19 test

  • by

As the Biden Administration pushes to offer more over-the-counter Covid-19 tests, the Food and Drug Administration authorized the first molecular Covid-19 test for over-the counter use. The test was developed by San Diego-based startup Cue Health.

Why hospitals want CMS, FTC to examine two UnitedHealthcare policies

  • by

Two UnitedHealthcare policies have raised several concerns among providers, including that they may display anti-competitive behavior and could block patient access to certain healthcare services. The American Hospital Association is asking the FTC and CMS to review and potentially block these policies.

4 takeaways from 23&Me’s planned SPAC deal

  • by

Consumer DNA testing company 23andMe plans to go public through a merger with a special-purpose acquisition company started by Virgin Group. As sales of DNA testing kits wane, how will 23andMe drum up new interest for its business?

What is the MedCity INVEST Pitch Perfect experience like?

  • by

The INVEST Pitch Perfect contest is part of our INVEST conference April 19-23, which will be hosted online due to Covid-19, and includes five tracks for startups: biopharma, medical devices, diagnostics, health IT and health services. Read more on how to apply.

Founders of molecular diagnostics company ChromaCode share ambitions for their business

  • by

ChromaCode’s founders seek to break the paradigm of limited access to the most powerful diagnostic tools by deploying inexpensive reagent kits and software using traditional PCR detection systems so physicians can initiate testing using the most informative diagnostics without having to worry about access or… Read More »Founders of molecular diagnostics company ChromaCode share ambitions for their business

Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics

  • by

Shots: The acquisition will integrate AmpTec’s PCR-based mRNA technology with Merck’s expertise in lipids manufacturing, providing combine offering across mRNA value chain The deal will expand Merck’s capabilities to develop & manufacture mRNA for use in vaccines, treatments, and diagnostics applicable in COVID-19 and many… Read More »Merck KGaA Acquires AmpTec to Strengthen its mRNA Capabilities for Vaccines, Treatments and Diagnostics

23andMe closes out 2020 with $82.5M in funding

  • by

DNA testing company 23andMe raised $82.5 million in funding, according to a recent filing. Earlier this year, decreased sales of tests kits led to cuts at the company and its competitors.

A proliferation of genetic testing options brings new challenges

  • by

In the last 20 years, access to genetic testing has expanded significant as technology has advanced. But there’s still lots of work to be done to get tests covered and make them more accessible, panelists said at a virtual conference hosted by MedCity News.

Which startups will present at MedCity INVEST Precision Medicine Pitch Perfect?

  • by

Among the areas of interest for companies presenting at Pitch Perfect at INVEST Precision Medicine are clinical stroke detection, making medical research more inclusive, using technology to accelerate the pace of clinical trials, developing more patient friendly drug delivery systems for reconstitutable drugs, and more.

Important questions about Pfizer’s Covid-19 vaccine

  • by

News of positive results from Pfizer’s Covid-19 vaccine is heartening but historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that have undergone extensive scrutiny about study design, results and assumptions, not through company press releases.

String of FDA approvals gives momentum to liquid biopsies

  • by

Following years of research and investment, liquid biopsies are steadily accumulating FDA approvals. The tests are being used in molecular profiling of solid tumors and as companion diagnostics for targeted cancer therapies.

The precision medicine conference you don’t want to miss

  • by

The summit gathers directors through the C-suite from across life science and healthcare sectors to discuss new developments in precision medicine, investment trends, and how health IT, diagnostics and biopharma technology are being used to improve outcomes.

Are Handheld Ultrasound Imaging Devices a True Revolution in Diagnostic Imaging Domain?

  • by

Advancements in the field of disease diagnostics have led to development of point-of-care medical imaging devices; handheld ultrasound scanners have emerged as a novel solution to cater to unmet need in this domain. These handheld ultrasound imaging devices are the lightest portable ultrasound devices, which… Read More »Are Handheld Ultrasound Imaging Devices a True Revolution in Diagnostic Imaging Domain?

Healthcare investing sets a new record in Q3

  • by

Global healthcare funding set a new record in the third quarter, according to data from CBInsights. Healthcare companies raised a total of $21.8 billion across 1,539 deals.

Lessons learned from Verily’s Covid-19 testing efforts

  • by

Google’s sister company launched a program in California and other states to help route patients to nearby coronavirus testing. Dr. Vivian Lee, president of health platforms for Verily, shared lessons learned from that effort and Verily’s work with schools and businesses.

Cue Health gets $481M to expand production of rapid coronavirus test

  • by

San Diego-based diagnostics startup Cue Health won a $481 million from the Department of Health and Human Services and the Department of Defense to produce more coronavirus tests. The company received an emergency use authorization in June for its rapid molecular test.

Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases

  • by

Shots: The agreement leverages Imbio’s technical, regulatory & commercial expertise to build medical imaging AI technology for use in research, clinical trials & clinical practice The focus of the agreement is to develop quantitative imaging diagnostics for lung diseases and to bring unique solutions for… Read More »Genentech Collaborates with Imbio to Develop Imaging Diagnostics for Lung Diseases

J.P. Morgan on the state of life sciences and strategies to fuel innovation [Sponsored]

  • by

In an interview, Peter Meath, J.P. Morgan’s co-head of Healthcare and Life Sciences, Middle Market Banking & Specialized Industries, says the Covid-19 pandemic has cast a bright light on the life sciences industry with startups raising venture funding at record levels as the virus has… Read More »J.P. Morgan on the state of life sciences and strategies to fuel innovation [Sponsored]

Why MedCity News should be your go-to advertising partner

  • by

MedCity News has the most engaged healthcare business audience in the industry. We can collaborate with you to develop customized content or provide a platform for your business to present sponsored thought leadership content highlighting from executives in healthcare and life sciences.

Founders’ Story: Truvian Sciences

  • by

In a Q&A, Truvian Sciences CEO Jeff Hawkins and Dena Marrinucci, founder and SVP Corporate Development and Business Operations talk about their point-of care blood testing technology.

Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease

  • by

Shots: The study involved 1402 patients across 3 cohorts: a) 81 patients in Arizona (34 with AD and 47 without), b) 699 in Sweden (301 with no cognitive impairment, 178 with mild cognitive impairment, 121 with AD dementia and 99 with other neurodegenerative diseases) and… Read More »Eli Lilly’s P-tau217 Blood Test Demonstrate High Accuracy in Diagnosis of Alzheimer’s Disease

Who won the MedCity INVEST Pitch Perfect competition?

  • by

Healthcare startups across health services, health IT, medical devices, biopharma and diagnostics tracks took part in the week-long competition at the conference July 20-24. Here are the winners for the five tracks.

Healthcare deals dip in 2020, but not as much as expected

  • by

Healthcare mergers decreased in the first half of 2020, but not to the extent expected as a result of the Covid-19 pandemic. Reports by Pricewaterhouse Coopers and Kaufman Hall showed a decline in mergers and acquisitions, but still reported sustained interest from buyers

A brief history of the future of genomics

  • by

Naysayers have been proven wrong multiple times over as companies across the biotech industry have advanced to deliver diagnostics and detection assays across a number of different cancer types enabling predictive testing, early diagnosis and objective results.